Antisomnogenic cytokines, quality of life, and chronic rhinosinusitis

A pilot study

Jeremiah A. Alt, Nathan Sautter, Jess C. Mace, Kara Y. Detwiller, Timothy Smith

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives/Hypothesis Sleep disturbance, reduced quality of life (QOL), and other components of "sickness behavior" in patients with chronic rhinosinusitis (CRS) are poorly understood. These complex changes in central behavior are due to the effects of immune mediators acting in the brain. We hypothesized that immune mediators that have been associated with CRS are also associated with sickness behavior, somnifacient complaints, and CRS disease-specific QOL. Study Design Pilot study. Methods Twenty patients with CRS were prospectively enrolled and completed the Pittsburgh Sleep Quality Index (PSQI), disease-specific QOL, and olfactory instruments. Ethmoid mucosa was obtained and reverse transcription-polymerase chain reaction was performed for the cytokines interleukin (IL)-4, -13, and transforming growth factor-β (TGF-β). Average change in crossover threshold was calculated, and differences in gene expression were correlated with sleep quality, CRS-specific QOL, and disease severity. Results Patients with CRS reported overall poor sleep quality and poor CRS-specific QOL with significant correlations between them. Increased expression of TGF-β (r = -0.443; P =.050) and IL-4 (r = -0.548; P =.012) correlated with sleep dysfunction, whereas IL-13 expression was linearly associated with worse sleep quality (PSQI scores r = -0.417; P =.075). IL-4 and TGF-β expression was not associated with CRS disease severity or QOL, whereas significantly higher levels of IL-13 expression correlated with worse CRS disease severity and QOL. Conclusions Patients with CRS exhibited behavioral changes commonly referred to as sickness behavior, which include poor sleep quality and reduced QOL. The upregulation of IL-4 and TGF-β may contribute to inflammatory brain-mediated effects on sleep quality, whereas IL-13 may be a pleiotropic signaling molecule influencing sleep, QOL, and CRS disease severity. Level of Evidence 2b. Laryngoscope, 124:E107-E114, 2014

Original languageEnglish (US)
JournalLaryngoscope
Volume124
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Sleep
Quality of Life
Cytokines
Interleukin-13
Transforming Growth Factors
Illness Behavior
Interleukin-4
Chronic Disease
Laryngoscopes
Brain
Reverse Transcription
Mucous Membrane
Up-Regulation
Gene Expression
Polymerase Chain Reaction

Keywords

  • inflammation mediators
  • quality of life
  • rhinology
  • Sinusitis
  • sleep

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Antisomnogenic cytokines, quality of life, and chronic rhinosinusitis : A pilot study. / Alt, Jeremiah A.; Sautter, Nathan; Mace, Jess C.; Detwiller, Kara Y.; Smith, Timothy.

In: Laryngoscope, Vol. 124, No. 4, 2014.

Research output: Contribution to journalArticle

Alt, Jeremiah A. ; Sautter, Nathan ; Mace, Jess C. ; Detwiller, Kara Y. ; Smith, Timothy. / Antisomnogenic cytokines, quality of life, and chronic rhinosinusitis : A pilot study. In: Laryngoscope. 2014 ; Vol. 124, No. 4.
@article{8ce882510d304ab2897d9e4ee0061651,
title = "Antisomnogenic cytokines, quality of life, and chronic rhinosinusitis: A pilot study",
abstract = "Objectives/Hypothesis Sleep disturbance, reduced quality of life (QOL), and other components of {"}sickness behavior{"} in patients with chronic rhinosinusitis (CRS) are poorly understood. These complex changes in central behavior are due to the effects of immune mediators acting in the brain. We hypothesized that immune mediators that have been associated with CRS are also associated with sickness behavior, somnifacient complaints, and CRS disease-specific QOL. Study Design Pilot study. Methods Twenty patients with CRS were prospectively enrolled and completed the Pittsburgh Sleep Quality Index (PSQI), disease-specific QOL, and olfactory instruments. Ethmoid mucosa was obtained and reverse transcription-polymerase chain reaction was performed for the cytokines interleukin (IL)-4, -13, and transforming growth factor-β (TGF-β). Average change in crossover threshold was calculated, and differences in gene expression were correlated with sleep quality, CRS-specific QOL, and disease severity. Results Patients with CRS reported overall poor sleep quality and poor CRS-specific QOL with significant correlations between them. Increased expression of TGF-β (r = -0.443; P =.050) and IL-4 (r = -0.548; P =.012) correlated with sleep dysfunction, whereas IL-13 expression was linearly associated with worse sleep quality (PSQI scores r = -0.417; P =.075). IL-4 and TGF-β expression was not associated with CRS disease severity or QOL, whereas significantly higher levels of IL-13 expression correlated with worse CRS disease severity and QOL. Conclusions Patients with CRS exhibited behavioral changes commonly referred to as sickness behavior, which include poor sleep quality and reduced QOL. The upregulation of IL-4 and TGF-β may contribute to inflammatory brain-mediated effects on sleep quality, whereas IL-13 may be a pleiotropic signaling molecule influencing sleep, QOL, and CRS disease severity. Level of Evidence 2b. Laryngoscope, 124:E107-E114, 2014",
keywords = "inflammation mediators, quality of life, rhinology, Sinusitis, sleep",
author = "Alt, {Jeremiah A.} and Nathan Sautter and Mace, {Jess C.} and Detwiller, {Kara Y.} and Timothy Smith",
year = "2014",
doi = "10.1002/lary.24412",
language = "English (US)",
volume = "124",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Antisomnogenic cytokines, quality of life, and chronic rhinosinusitis

T2 - A pilot study

AU - Alt, Jeremiah A.

AU - Sautter, Nathan

AU - Mace, Jess C.

AU - Detwiller, Kara Y.

AU - Smith, Timothy

PY - 2014

Y1 - 2014

N2 - Objectives/Hypothesis Sleep disturbance, reduced quality of life (QOL), and other components of "sickness behavior" in patients with chronic rhinosinusitis (CRS) are poorly understood. These complex changes in central behavior are due to the effects of immune mediators acting in the brain. We hypothesized that immune mediators that have been associated with CRS are also associated with sickness behavior, somnifacient complaints, and CRS disease-specific QOL. Study Design Pilot study. Methods Twenty patients with CRS were prospectively enrolled and completed the Pittsburgh Sleep Quality Index (PSQI), disease-specific QOL, and olfactory instruments. Ethmoid mucosa was obtained and reverse transcription-polymerase chain reaction was performed for the cytokines interleukin (IL)-4, -13, and transforming growth factor-β (TGF-β). Average change in crossover threshold was calculated, and differences in gene expression were correlated with sleep quality, CRS-specific QOL, and disease severity. Results Patients with CRS reported overall poor sleep quality and poor CRS-specific QOL with significant correlations between them. Increased expression of TGF-β (r = -0.443; P =.050) and IL-4 (r = -0.548; P =.012) correlated with sleep dysfunction, whereas IL-13 expression was linearly associated with worse sleep quality (PSQI scores r = -0.417; P =.075). IL-4 and TGF-β expression was not associated with CRS disease severity or QOL, whereas significantly higher levels of IL-13 expression correlated with worse CRS disease severity and QOL. Conclusions Patients with CRS exhibited behavioral changes commonly referred to as sickness behavior, which include poor sleep quality and reduced QOL. The upregulation of IL-4 and TGF-β may contribute to inflammatory brain-mediated effects on sleep quality, whereas IL-13 may be a pleiotropic signaling molecule influencing sleep, QOL, and CRS disease severity. Level of Evidence 2b. Laryngoscope, 124:E107-E114, 2014

AB - Objectives/Hypothesis Sleep disturbance, reduced quality of life (QOL), and other components of "sickness behavior" in patients with chronic rhinosinusitis (CRS) are poorly understood. These complex changes in central behavior are due to the effects of immune mediators acting in the brain. We hypothesized that immune mediators that have been associated with CRS are also associated with sickness behavior, somnifacient complaints, and CRS disease-specific QOL. Study Design Pilot study. Methods Twenty patients with CRS were prospectively enrolled and completed the Pittsburgh Sleep Quality Index (PSQI), disease-specific QOL, and olfactory instruments. Ethmoid mucosa was obtained and reverse transcription-polymerase chain reaction was performed for the cytokines interleukin (IL)-4, -13, and transforming growth factor-β (TGF-β). Average change in crossover threshold was calculated, and differences in gene expression were correlated with sleep quality, CRS-specific QOL, and disease severity. Results Patients with CRS reported overall poor sleep quality and poor CRS-specific QOL with significant correlations between them. Increased expression of TGF-β (r = -0.443; P =.050) and IL-4 (r = -0.548; P =.012) correlated with sleep dysfunction, whereas IL-13 expression was linearly associated with worse sleep quality (PSQI scores r = -0.417; P =.075). IL-4 and TGF-β expression was not associated with CRS disease severity or QOL, whereas significantly higher levels of IL-13 expression correlated with worse CRS disease severity and QOL. Conclusions Patients with CRS exhibited behavioral changes commonly referred to as sickness behavior, which include poor sleep quality and reduced QOL. The upregulation of IL-4 and TGF-β may contribute to inflammatory brain-mediated effects on sleep quality, whereas IL-13 may be a pleiotropic signaling molecule influencing sleep, QOL, and CRS disease severity. Level of Evidence 2b. Laryngoscope, 124:E107-E114, 2014

KW - inflammation mediators

KW - quality of life

KW - rhinology

KW - Sinusitis

KW - sleep

UR - http://www.scopus.com/inward/record.url?scp=84896545684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896545684&partnerID=8YFLogxK

U2 - 10.1002/lary.24412

DO - 10.1002/lary.24412

M3 - Article

VL - 124

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 4

ER -